Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
about
Assessing the Immunogenicity of BiopharmaceuticalsComparative immunogenicity assessment: a critical consideration for biosimilar development.Fundamentals of large-molecule protein therapeutic bioanalysis using ligand-binding assays.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
P2860
Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Challenges of developing and v ...... r biosimilar drug development.
@en
type
label
Challenges of developing and v ...... r biosimilar drug development.
@en
prefLabel
Challenges of developing and v ...... r biosimilar drug development.
@en
P2093
P2860
P356
P1433
P1476
Challenges of developing and v ...... r biosimilar drug development.
@en
P2093
Constance Cullen
Dominique Gouty
Jeff Thomas
Xiao-Yan Cai
P2860
P304
P356
10.4155/BIO.12.185
P577
2012-09-01T00:00:00Z